Premium
Ibrutinib: the first Bruton's tyrosine kinase inhibitor
Author(s) -
Chaplin Steve
Publication year - 2018
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1691
Subject(s) - ibrutinib , bruton's tyrosine kinase , medicine , mantle cell lymphoma , tyrosine kinase , cancer research , chronic lymphocytic leukemia , tyrosine kinase inhibitor , lymphoma , immunology , leukemia , cancer , receptor
Bruton's tyrosine kinase (BTK) is emerging as a promising target in the treatment of B‐cell malignancies. This article discusses the properties of the first licensed BTK inhibitor, ibrutinib (Imbruvica) and its place in the management of mantle cell lymphoma, chronic lymphocytic leukaemia and Waldenström's macroglobulinaemia.